Findings

What do systematic reviews say?

22 questions · 22 findings · 1 reviews · Periodontology

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 13.6%GRADE not reported 12 · 54.5%Very low 0 · 0%Low 7 · 31.8%Moderate 0 · 0%High 0 · 0%

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

Postoperative complications (infection) / adverse events · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
No particular adverse events or infection attributable to EMD in any trial; no differences in pain, edema, hematoma, wound dehiscence or root sensitivity (Tonetti 2002).
9 studies
GRADE not reported

Enamel matrix derivative (EMD; Emdogain) vs placebo or control

PAL gain < 2 mm (dichotomous) · Patients affected by chronic, aggressive, or early onset periodontitis, with intrabony defects having an intrabony component of at least 3…

Enamel matrix derivative (EMD; Emdogain) led to lower PAL gain < 2 mm (dichotomous) compared with placebo or control (same surgical or non-surgical intervention…; GRADE not reported.

1 finding from 1 review

Enamel matrix derivative (Emdogain®) for periodontal tissue regeneration in intrabony defects 2009 · Cochrane All outcomes
1 year (time-points 1, 5 and 10 years planned)
RR 0.53 [0.34, 0.82]
6 studies
GRADE not reported